Evaluaciones económicas

Published on 15 de marzo de 2022 | http://doi.org/10.5867/medwave.2022.02.002118

Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru

Back to article Table 8.

Budget impact from the Ministry of Health and and the Social Security Health Insurance (US$), in adults and children, comparing current scheme with emicizumab prophylaxis (US$).